GOSSAMER BIO, INC. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- GOSSAMER BIO, INC. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $220.00K, a 66.67% increase year-over-year.
- GOSSAMER BIO, INC. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $465.00K.
- GOSSAMER BIO, INC. stock issued during period, value, stock options exercised for the quarter ending 2025-06-30 was $94.00K.
- GOSSAMER BIO, INC. stock issued during period, value, stock options exercised for the quarter ending 2025-03-31 was $132.00K.
- GOSSAMER BIO, INC. stock issued during period, value, stock options exercised for fiscal 2025 was $1.93M.
- GOSSAMER BIO, INC. stock issued during period, value, stock options exercised for fiscal 2022 was $1.74M, a 13.80% decline from fiscal 2021.
- GOSSAMER BIO, INC. stock issued during period, value, stock options exercised for fiscal 2021 was $2.01M, a 277.15% increase from fiscal 2020.
- GOSSAMER BIO, INC. stock issued during period, value, stock options exercised for fiscal 2020 was $534.00K, a 73.89% decline from fiscal 2019.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-03-31 | $220.00K 10-Q · filed 2026-08-13 | |
| 2025-12-31 | $1.93M 10-K · filed 2026-03-17 | |
| 2025-09-30 | $465.00K 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $94.00K 10-Q · filed 2026-08-13 | |
| 2025-03-31 | $132.00K 10-Q · filed 2026-08-13 | |
| 2022-12-31 | $1.74M 10-K · filed 2025-03-13 | |
| 2022-09-30 | $1.58M 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $21.00K 10-Q · filed 2023-11-09 | |
| 2022-03-31 | $126.00K 10-Q · filed 2023-11-09 | |
| 2021-12-31 | $2.01M 10-K · filed 2024-03-05 | |
| 2021-09-30 | $1.36M 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $271.00K 10-Q · filed 2022-11-03 | |
| 2021-03-31 | $15.00K 10-Q · filed 2022-11-03 | |
| 2020-12-31 | $534.00K 10-K · filed 2023-03-17 | |
| 2020-09-30 | $131.00K 10-Q · filed 2021-11-08 | |
| 2020-06-30 | $139.00K 10-Q · filed 2021-11-08 | |
| 2020-03-31 | $15.00K 10-Q · filed 2021-11-08 | |
| 2019-12-31 | $2.04M 10-K · filed 2022-03-03 | |
| 2019-09-30 | $369.00K 10-Q · filed 2020-11-10 | |
| 2019-06-30 | $86.00K 10-Q · filed 2020-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 |